Dr. Tyson has pioneered the development of experimental and computational approaches to assess the dynamics of cancer therapeutic response at the single-cell level to better understand the mechanisms of anticancer drug action and the progression to treatment resistance. His recent research has focused on evaluating the role of biochemical networks and signaling mechanisms controlling stochastic cell fate decisions—including phenotypic plasticity—as they relate to mechanisms of resistance to anticancer therapies. He also has extensive knowledge on the assessment and quantification of synergy of drug combinations in the preclinical setting.

Dr. Tyson received his Ph.D. in Cell and Molecular Biology from Saint Louis University, received postdoctoral training at the University of California, Irvine, and is currently a Research Associate Professor of Biochemistry with a joint appointment in Pharmacology in the Vanderbilt University School of Medicine. He is also a member of the Vanderbilt-Ingram Cancer Center, the Center for Cancer Systems Biology, and the Quantitative Systems Biology Center at Vanderbilt University. He has been part of a U.S. National Cancer Institute Consortium for Cancer Systems Biology for nearly 15 years.